Clinical Trials Browser

Interventional × Meningioma × Bevacizumab × Clear all

NCT06955169 2026-05-22

MOMENTUM-1

Phase 2 Suspended

Meningioma

NCT04374305 2026-05-06

INTUITT-NF2

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT06326190 2025-09-16

LUMEN-1

Phase 2 Recruiting

Meningioma

NCT02847559 2025-06-27

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Phase 2 Recruiting

Meningioma

NCT00972335 2021-11-10

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase 2 Terminated

18 enrolled 5 charts

Meningioma

NCT01125046 2021-01-22

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Phase 2 Completed

50 enrolled 13 charts

Brain Neoplasms, Ependymoma, Meningioma, Neurofibromatosis 1, Neuroma, Acoustic, Neurofibromatosis 2

NCT00492089 2014-05-09

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Phase 2 Completed

11 enrolled 7 charts

Hemangiopericytoma, Malignant, Squamous Cell Carcinoma of Head and Neck, Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Radiation Injuries, Salivary Gland Neoplasms, Choroid Plexus Neoplasms, Esthesioneuroblastoma, Olfactory